CVE-2017-17678

BMC Remedy Mid Tier 9.1SP3 is affected by cross-site scripting (XSS). A DOM-based cross-site scripting vulnerability was discovered in a legacy utility.
Configurations

Configuration 1 (hide)

cpe:2.3:a:bmc:remedy_mid-tier:9.1:sp3:*:*:*:*:*:*

History

01 Jun 2021, 17:14

Type Values Removed Values Added
References (MISC) http://bmc.com - (MISC) http://bmc.com - Product
References (MISC) https://docs.bmc.com/docs/ars91/en/9-1-00-fixes-available-for-remedy-ar-system-security-vulnerabilities-800555806.html - (MISC) https://docs.bmc.com/docs/ars91/en/9-1-00-fixes-available-for-remedy-ar-system-security-vulnerabilities-800555806.html - Release Notes, Vendor Advisory
References (MISC) https://seclists.org/fulldisclosure/2017/Oct/52 - (MISC) https://seclists.org/fulldisclosure/2017/Oct/52 - Mailing List, Third Party Advisory
References (MISC) http://remedy.com - (MISC) http://remedy.com - Product
CVSS v2 : unknown
v3 : unknown
v2 : 4.3
v3 : 6.1
CWE CWE-79
CPE cpe:2.3:a:bmc:remedy_mid-tier:9.1:sp3:*:*:*:*:*:*

19 May 2021, 14:15

Type Values Removed Values Added
New CVE

Information

Published : 2021-05-19 14:15

Updated : 2023-12-10 13:55


NVD link : CVE-2017-17678

Mitre link : CVE-2017-17678

CVE.ORG link : CVE-2017-17678


JSON object : View

Products Affected

bmc

  • remedy_mid-tier
CWE
CWE-79

Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting')